Trial Profile
A phase II study of neoadjuvant SU011248 (sunitinib) in metastatic renal cell carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2006
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 07 Sep 2006 New trial record.